WO2010007100A1 - Amino triazoles substitués en position 7 en tant qu’inhibiteurs de pi3k - Google Patents

Amino triazoles substitués en position 7 en tant qu’inhibiteurs de pi3k Download PDF

Info

Publication number
WO2010007100A1
WO2010007100A1 PCT/EP2009/059076 EP2009059076W WO2010007100A1 WO 2010007100 A1 WO2010007100 A1 WO 2010007100A1 EP 2009059076 W EP2009059076 W EP 2009059076W WO 2010007100 A1 WO2010007100 A1 WO 2010007100A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
pyridin
triazolo
optionally substituted
halogen
Prior art date
Application number
PCT/EP2009/059076
Other languages
English (en)
Inventor
Nigel Ramsden
Kathryn Bell
Andrew Cansfield
Jess Taylor
Mihiro Sunose
David Middlemiss
Katie Ellard
Original Assignee
Cellzome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ltd filed Critical Cellzome Ltd
Publication of WO2010007100A1 publication Critical patent/WO2010007100A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a novel class of kinase inhibitors, including pharmaceutically acceptable salts, prodrugs and metabolites thereof, which are useful for modulating protein kinase activity for modulating cellular activities such as signal transduction, proliferation, differentiation, programmed cell death, migration and cytokine secretion. More specifically the invention provides compounds which inhibit, regulate and/or modulate kinase activity, in particular PBK activity, and signal transduction pathways relating to cellular activities as mentioned above. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds, e.g. for the treatment of diseases such as immunological, inflammatory, autoimmune and allergic disorders, and processes for preparing said compounds.
  • diseases such as immunological, inflammatory, autoimmune and allergic disorders
  • Protein and lipid kinases participate in the signaling events which control the activation, growth, differentiation and survival of cells in response to extracellular mediators or stimuli such as growth factors, cytokines or chemokines.
  • protein kinases are classified in two groups, those that preferentially phosphorylate tyrosine residues and those that preferentially phosphorylate serine and/or threonine residues in their protein substrates.
  • lipid kinases phosphorylate a variety of lipid substrates.
  • Inappropriately high protein or lipid kinase activity is involved in many diseases including cancer, metabolic diseases, immunological diseases and inflammatory disorders. This can be caused either directly or indirectly by the failure of control mechanisms due to mutation, overexpression or inappropriate activation of the enzyme. In all of these instances, selective inhibition of the kinase is expected to have a beneficial therapeutic effect.
  • Phosphoinositide 3-kinases also called Phosphatidylinositol 3-kinases, PBKs
  • PBKs Phosphatidylinositol 3-kinases
  • Some members of the PBK family also display protein kinase activity (Vanhaesebroeck et al., 2001, Annu. Rev. Biochem. 70:535-602).
  • PBKs belongs to a superfamily of signaling lipid kinases that catalyse the phosphorylation of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2 or phosphatidylinositol (Ptdlns) at the 3'-OH group, giving rise to the second messengers phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) or phosphatidylinosito 1-3 -phosphate (PtdIns(3)P).
  • PtdIns(3,4,5)P3 can be converted into PtdIns(3,4)P2 by SH2-containing inositol phosphatase (SHIP), or can be dephosphorylated by phosphatase and tensin homologue (PTEN) phosphatase to regenerate PtdIns(4,5)P2.
  • SHIP SH2-containing inositol phosphatase
  • PTEN tensin homologue
  • PtdIns(3,4,5)P3, PtdIns(3,4)P2 PtdIns(4,5)P2, PtdIns(5)P and PtdIns(3)P recruit and activate various signalling proteins (Ptdlnsbinding proteins; Ptdlns-BPs) through direct lipid-protein interactions (Hawkins et al., 2006, Biochem. Soc. Trans. 34:647-62).
  • Phosphatidylinositol-3,4,5-trisphosphate has an important role as second messenger by working as a docking platform for lipid-binding domains, such as the pleckstrin homology (PH) domains of various cellular proteins.
  • lipid-binding domains such as the pleckstrin homology (PH) domains of various cellular proteins.
  • kinases such as 3- phosphoinositide-dependent protein kinase 1 (PDKl) and protein kinase B (PKB)/Akt
  • guanine -nucleotide exchange factors such as Vav and P-Rex
  • PI3 -kinase activation is believed to be involved a variety of signal transduction pathways, including those essential to cell proliferation, cell differentiation, cell growth, cell survival, apoptosis, adhesion, chemotaxis, invasion, cytoskeletal rearrangement, contraction, phagocytosis vesicle trafficking, receptor internalization, secretion, protein synthesis and metabolic pathways.
  • PI3K gamma ( ⁇ ) and delta ( ⁇ ) isoforms appear to be involved in a number of aspects of leukocyte activation (Rommel et al., 2007, Nat. Rev. Immunol. 7(3):191-201; Ruckle et al., 2006, Nat. Rev. Drug Discov. 5(l l):903-18).
  • PI3K Different types have been identified and grouped into three classes according to their primary and secondary structures, mode of regulation and substrate specificity.
  • Class I PI3K has been the most extensively studied so far, and includes heterodimeric proteins that consist of a catalytic and a regulatory adaptor subunit, the nature of which determines a further subdivision into class IA and IB PI3K.
  • Class II PI3K uses Ptdlns as in vivo substrate, yielding phosphatidylinositol-3-phosphate (PtdIns(3)P).
  • class II enzymes similarly to class I can be activated by external stimuli via receptor tyrosine kinases (RTKs), cytokine receptors and integrins, suggesting roles in cancer, wound healing and insulin signaling.
  • RTKs receptor tyrosine kinases
  • cytokine receptors cytokine receptors
  • integrins integrins
  • the class III represents the most ancient form of PBK and it uses exclusively Ptdlns as a substrate to produce PtdIns(3)P. This class of PBKs is involved in endocytic membrane traffic, phagosom maturation and autophagy (Falasca et al, 2007, Biochem. Soc. Trans. 35:211-4; Lindmo et al, 2006, J. Cell Sci. 119:605-14).
  • the class IA - PBK ⁇ , ⁇ and ⁇ (PIK3CA, PIK3CB and PIK3CD) - consists of an SH2-domain- containing regulatory subunit (p85; five distinct isoforms of which have been identified) that forms a complex with one of three catalytic subunits, pl lO ⁇ , pl lO ⁇ or pl lO ⁇ . (Bader et al., 2005, Nat. Rev. Cancer 5(12):921-9).
  • PBK pathway Genetic polymorphisms within the PBK pathway are also associated with an increased risk of type 2 diabetes. Downstream of the insulin-like growth factor 1 (IGFl) receptor, signaling through class I PBK controls growth and development. Amplification and point mutations of the gene encoding PBK ⁇ that increase the enzymatic activity of the protein have been frequently found in human cancers (Bader et al., 2005, Nat. Rev. Cancer 5(12):921-9).
  • IGFl insulin-like growth factor 1
  • PBK activation and PIP3 production are fundamental for most biological responses exerted by insulin.
  • Activated insulin receptor (IR) triggers PBK activity by binding and phosphorylating adaptor proteins of the insulin receptor substrate (IRS) family.
  • IRS insulin receptor substrate
  • phoshphorylation IRS serves as a docking site for p85 regulatory subunits that consequently recruit pi 10 enzymes (mainly ⁇ and ⁇ isoforms).
  • PIP3 production in turn activates downstream effectors that control various metabolic processes such as glucose uptake, triglyceride formation, glycogen synthesis, lipolysis and hepatic gluconeogenesis inhibition
  • PBK ⁇ has been implicated in regulating the formation and stability of integrin ⁇ (IIb) ⁇ (3), which is necessary for the activation and aggregation of platelets.
  • Isoform-selective PBK pl lO ⁇ inhibitors have been developed which in vivo eliminate occlusive thrombus formation but do not prolong bleeding time. These studies define PBK pi lO ⁇ as an important new target for antithrombotic therapy (Jackson et al., 2005, Nat. Med. 11 (5):507-14).
  • PBK ⁇ is predominantly expressed in the haematopoietic system and PBK ⁇ -deficient mice are viable, fertile, apparently healthy and have a normal life span (Vanhaesebroeck et al., 2005. Trends in Biochemical Sciences 30, 194-204).
  • PBK ⁇ has important roles in T- and B-cell signaling, mast-cell-mediated allergic responses, the neutrophils oxidative burst and, possibly, extravasation.
  • PBK inhibitors selective for PBK ⁇ were reported to block neutrophil activation in an animal model for neutrophil activation, thus pointing to PBk ⁇ as a target for the development of anti-inflammatory drugs (Sadhu et al., 2003, Biochem. Biophys. Res. Communications 308, 764-769).
  • PBKy the only member of class IB (PIK3CG), associates with either of two regulatory subunits, plOl and p84, that control its activation and subcellular location.
  • PBKy activation is driven by the direct association of its catalytic domain with the ⁇ subunits of G proteins following activation of pertussis-toxin-sensitive G ⁇ i-coupled G-protein-coupled receptors (GPCRs).
  • GPCRs GPCRs
  • PBK ⁇ can be activated by Ras by a direct interaction with the catalytic subunit. Beside its lipid kinase activity, PBK ⁇ has a protein kinase activity. It uses the regulatory subunits as well as itself as substrate and both events result in an increase of the lipid kinase activity (Leopoldt et al., 1998, J. Biol. Chem. 273(12):7024-9).
  • PDEs phosphodiesterases
  • mice lacking functional PBK ⁇ were viable, fertile, and displayed a normal life span in a conventional mouse facility. Further studies revealed that neutrophils of these mice were unable to produce Ptdlns (3,4,5) P3 when stimulated with GPCR agonists such as formylated bacterial peptides (N- formyl-Met-Leu-Phe, fMLP), complement C5a or interleukin 8 (IL-8). This observation demonstrates that PBK ⁇ is the sole PBK isoform that is coupled to these GPCRs in neutrophils (Vanhaesebroeck et al., 2005.
  • GPCR agonists such as formylated bacterial peptides (N- formyl-Met-Leu-Phe, fMLP), complement C5a or interleukin 8 (IL-8).
  • Pi3kcg-/- mice showed impaired thymocyte development and increases in neutrophil, monocyte, and eosinophil populations. Furthermore, neutrophils and macrophages isolated from Pi3kcg-/-mice exhibited severe defects in migration and respiratory burst in response to GPCR agonists and chemotactic agents.
  • PBK ⁇ is required for the homing of dendritic cells to lymph nodes and in the development and activation of T lymphocytes (together with PBK ⁇ ).
  • PBK ⁇ also contributes to the activation of mast cell secretion by adenosine. Its involvement in the stimulation of autocrine and paracrine regulatory loops by purines has also been observed in other cell types.
  • PBK ⁇ also contributes to the activation of platelet aggregation by ADP in concert with PBK ⁇ (Ferguson et al., 2007, Nat. Cell Biol. 9(1):86-91).
  • PBK ⁇ plays a crucial role in both vascular cells and white blood cells. It controls diverse immune modulatory and vascular functions like respiratory burst, cell recruitment, mast cell reactivity, platelet aggregation, endothelial activation as well as smooth muscle contractility. The relative specificity of these events suggests that blocking PBK ⁇ function might turn out beneficial for diseases like inflammation, allergy, autoimmunity, thrombosis, and major cardiovascular disorders like hypertension and atherosclerosis (Hirsch et al., 2006, Thromb. Haemost. 95(l):29-35). In addition, it was demonstrated that PBK ⁇ plays a role in a mouse model for pancreatitis.
  • mice lacking PBK ⁇ The lethality of the choline-deficient/ethionine-supplemented diet- induced pancreatitis was significantly reduced in mice lacking PBK ⁇ (Lupia et al., 2004. Am. J. Pathol. 165(6):2003-2011).
  • PI-3 Kinase inhibitors are described in WO-A 2007/095588.
  • an object of the present invention is to provide a new class of compounds as kinase inhibitors, especially as PBK inhibitors, which may be effective in the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders or other diseases or disorders associated with PBK. Furthermore, another object of the present invention is to provide said compounds, which may be effective in the treatment or prophylaxis of cancer or cardiovascular disorders associated with PBK.
  • R 1 , R 2 , R 3 are independently selected from the group consisting of H; halogen; CN; C(O)OR 4 ; OR 4 ; C(O)R 4 ; C(O)N(R 4 R 4a ); S(O) 2 N(R 4 R 4a ); S(O)N(R 4 R 4a ); S(O) 2 R 4 ; S(O)R 4 ; N(R 4 )S(O) 2 N(R 4a R 4b ); N(R 4 )S(O)N(R 4a R 4b ); SR 4 ; N(R 4 R 4a ); OC(O)R 4 ; N(R 4 )C(O)R 4a ; N(R 4 )S(O) 2 R 4a ; N(R 4 )S(O)R 4a ; N(R 4 )C(O)N(R 4a R 4b ); N(R 4 )C(O)OR 4a ; OC(O
  • Ci_6 alkyl wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • R 4 , R 4a , R 4b are independently selected from the group consisting of H; and Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • T 1 is 4 to 7 membered heterocyclyl; 8 to 11 membered heterobicyclyl; phenyl; naphthyl; indenyl; or indanyl; wherein T 1 is optionally substituted with one or more R 5 and/or one or more R 6 ;
  • Ci_6 alkyl wherein Ci_6 alkyl is optionally substituted with one or more R 8 ;
  • R 6 is T 2 ; C(O)OR 9 ; OR 9 ; C(O)R 9 ; C(O)N(R 9 R 9a ); S(O) 2 N(R 9 R 9a ); S(O)N(R 9 R 9a ); S(O) 2 R 9 ; S(O)R 9 ; N(R 9 )S(O) 2 N(R 9a R 9b ); N(R 9 )S(O)N(R 9a R 9b ); SR 9 ; N(R 9 R 9a ); OC(O)R 9 ; N(R 9 )C(O)R 9a ; N(R 9 )S(O) 2 R 9a ; N(R 9 )S(O)R 9a ; N(R 9 )C(O)N(R 9a R 9b ); N(R 9 )C(O)OR 9a ; OC(O)N(R 9 R 9a ); or Ci_6 alkyl substituted with one
  • R 9 , R 9a , R 9b are independently selected from the group consisting of R 9c ; and R 9d , provided that at least one of R 9 , R 9a , R 9b is R 9c ;
  • R 9c is T 2 ; or Ci_6 alkyl, wherein Ci_6 alkyl is substituted with one or more T 2 and optionally substituted with one or more R 8 ;
  • R 7 , R 7a , R 7b , R 9d are independently selected from the group consisting of H; and Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more R 8 ;
  • R 8 is halogen; CN; C(O)OR 10 ; OR 10 ; C(O)R 10 ; C(O)N(R 10 R 10a ); S(O) 2 N(R 10 R 1 Oa );
  • Ci_ 6 alkyl wherein Ci -6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • R 10 , R 1Oa , R 10b are independently selected from the group consisting of H; and Ci_ 6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • Ci_ 6 alkyl N(R 12 )C(O)OR 12a ; OC(O)N(R 12 R 12a ); or Ci_ 6 alkyl, wherein Ci -6 alkyl is optionally substituted with one or more halogen which are the same or different;
  • R 12 , R 12a , R 12b are independently selected from the group consisting of H; and Ci_ 6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • variable or substituent can be selected from a group of different variants and such variable or substituent occurs more than once the respective variants can be the same or different.
  • alkyl means a straight-chain or branched carbon chain that may contain double or triple bonds. It is generally preferred that alkyl doesn't contain double or triple bonds.
  • alkyl includes within the meaning of the present invention alkyl groups as well as alkenyl and alkinyl groups. Each hydrogen of an alkyl carbon may be replaced by a substituent.
  • Ci_4 alkyl includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. Each hydrogen of a Ci_ 4 alkyl carbon may be replaced by a substituent.
  • Ci_6 alkyl includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl, n-pentyl, and n-hexyl.
  • Each hydrogen of a Ci_ 6 alkyl carbon may be replaced by a substituent.
  • C 3 _ 7 cycloalkyl or “C 3 _ 7 cycloalkyl ring” means a cyclic alkyl chain having 3 - 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent.
  • Halogen means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.
  • Examples for a 4 to 7 membered heterocycles are azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydro furan, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyr
  • 8 to 11 membered heterobicyclyl or “8 to 11 membered heterobicycle” means a heterocyclic system of two rings with 8 to 11 ring atoms, where at least one ring atom is shared by both rings and that may contain up to the maximum number of double bonds
  • 11 membered heterobicycle are indole, indoline, benzo furan, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine.
  • 8 to 11 membered heterobicycle also includes spiro structures of two rings like l,4-dioxa-8-azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane.
  • Preferred compounds of formula (I) are those compounds in which one or more of the residues contained therein have the meanings given below, with all combinations of preferred substituent definitions being a subject of the present invention.
  • the present invention also includes all tautomeric and stereoisomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts.
  • substituents mentioned below independently have the following meaning. Hence, one or more of these substituents can have the preferred or more preferred meanings given below.
  • X is N; or CH, preferably N; and R 5a is H; R 5 ; or R 6 , preferably R 5 or R 6 , even more preferably, R 5 .
  • T 1 is unsubstituted phenyl; substituted phenyl; unsubstituted 4 to 7 membered heterocyclyl; substituted 4 to 7 membered heterocyclyl; unsubstituted 8 to 11 membered heterobicyclyl; or substituted 8 to 11 membered heterobicyclyl.
  • T 1 is phenyl; pyrrolyl; furyl; thienyl; oxazolyl; thiazolyl; pyridyl and N-oxide thereof; pyrimidinyl; indolyl; indolinyl; indazolyl; quinolinyl, isoquinolinyl, benzodioxolyl, dihydrobenzo furyl; dihydrobenzoxazinyl; benzodioxanyl; benzothiazole dioxide. More preferred T 1 is phenyl or pyridyl.
  • T 1 is unsubstituted, substituted with one R 5 , two R 5 , one R 6 , two R 6 , or one R 5 and one R 6
  • R 7 , R 7a are independently selected from the group consisting of H; CH 3 ; CH 2 CH 3 ;
  • R 7 , R 7a are independently selected from the group consisting of H; CH 3 ; CH 2 CH 3 ; CH 2 CH 2 CH 3 ; n-butyl; tert.-butyl; iso-propyl; and 2-ethylbutyl.
  • R 8 is F; Cl; Br; OH; CH 3 ; or CH 2 CH 3 .
  • R 6 is S(O) 2 N(R 9 R 9a ); N(R 9 )S(O) 2 R 9a ; S(O) 2 R 9 ; or OR 9 .
  • R 6 is S(O) 2 N(R 9c R 9d ); N(R 9d )S(O) 2 R 9c ; S(O) 2 R 9c ; or OR 9c .
  • R 9c is T 2 or CH 2 -T 2 .
  • R 9d is H or methyl.
  • T 2 is phenyl; naphthyl; C 3 _4 cycloalkyl; or 4 to 7 membered heterocyclyl, wherein T 2 is optionally substituted with up to three R 11 .
  • T 2 phenyl; naphthyl; cyclopropyl; cyclobutyl; or azetidine wherein T 2 is optionally substituted with up to three R 11 .
  • Prodrugs of the compounds of the present invention are also within the scope of the present invention.
  • Prodrug means a derivative that is converted into a compound according to the present invention by a reaction with an enzyme, gastric acid or the like under a physiological condition in the living body, e.g. by oxidation, reduction, hydrolysis or the like, each of which is carried out enzymatically.
  • Examples of a prodrug are compounds, wherein the amino group in a compound of the present invention is acylated, alkylated or phosphorylated to form, e.g., eicosanoylamino, alanylamino, pivaloyloxymethylamino or wherein the hydroxyl group is acylated, alkylated, phosphorylated or converted into the borate, e.g.
  • Metabolites of compounds of formula (I) are also within the scope of the present invention.
  • metabolites refers to all molecules derived from any of the compounds according to the present invention in a cell or organism, preferably mammal.
  • the term relates to molecules which differ from any molecule which is present in any such cell or organism under physiological conditions
  • tautomerism like e.g. keto-enol tautomerism
  • the individual forms like e.g. the keto and enol form, are comprised separately and together as mixtures in any ratio.
  • stereoisomers like e.g. enantiomers, cis/trans isomers, conformers and the like.
  • isomers can be separated by methods well known in the art, e.g. by liquid chromatography.
  • enantiomers by using e.g. chiral stationary phases.
  • enantiomers may be isolated by converting them into diastereomers, i.e.
  • any enantiomer of a compound of formula (I) may be obtained from stereoselective synthesis using optically pure starting materials.
  • the invention also comprises their corresponding pharmaceutically or toxico logically acceptable salts, in particular their pharmaceutically utilizable salts.
  • the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
  • Compounds of the formula (I) which contain one or more basic groups i.e.
  • acids which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids.
  • suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art.
  • the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions).
  • the respective salts according to the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.
  • the present invention also includes all salts of the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
  • pharmaceutically acceptable means approved by a regulatory agency such as the EMEA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.
  • the present invention furthermore includes all solvates of the compounds according to the invention.
  • the present invention provides compounds of formula (I) as kinase inhibitors, especially as PBK inhibitors.
  • the compounds of the present invention are useful for the prevention or treatment of immunological disorders (e.g. immune or autoimmune diseases), inflammatory disorders or allergic disorders.
  • Another object of the present invention is a compound of the present invention or a pharmaceutically acceptable salt thereof for use as a medicament.
  • Another object of the present invention is a compound or a pharmaceutically acceptable salt thereof according to the present invention for use in a method of treating or preventing diseases and disorders associated with PBK.
  • Yet another object of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prophylaxis of diseases and disorders associated with PBK, preferably PBK ⁇ .
  • R 1 , R 2 , R 3 are independently selected from the group consisting of H; halogen; CN; C(O)OR 4 ; OR 4 ; C(O)R 4 ; C(O)N(R 4 R 4a ); S(O) 2 N(R 4 R 4a ); S(O)N(R 4 R 4a ); S(O) 2 R 4 ; S(O)R 4 ; N(R 4 )S(O) 2 N(R 4a R 4b ); N(R 4 )S(O)N(R 4a R 4b ); SR 4 ; N(R 4 R 4a ); OC(O)R 4 ; N(R 4 )C(O)R 4a ; N(R 4 )S(O) 2 R 4a ; N(R 4 )S(O)R 4a ; N(R 4 )C(O)N(R 4a R 4b ); N(R 4 )C(O)OR 4a ; OC(O
  • R 4 , R 4a , R 4b are independently selected from the group consisting of H; and Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • T 1 is 4 to 7 membered heterocyclyl; 8 to 11 membered heterobicyclyl; phenyl; naphthyl; indenyl; or indanyl; wherein T 1 is optionally substituted with one or more R 5 and/or one or more R 6 ;
  • Ci_6 alkyl wherein Ci_6 alkyl is optionally substituted with one or more R 8 ;
  • R 6 is T 2 ; C(O)OR 9 ; OR 9 ; C(O)R 9 ; C(O)N(R 9 R 9a ); S(O) 2 N(R 9 R 9a ); S(O)N(R 9 R 9a ); S(O) 2 R 9 ; S(O)R 9 ; N(R 9 )S(O) 2 N(R 9a R 9b ); N(R 9 )S(O)N(R 9a R 9b ); SR 9 ; N(R 9 R 9a ); OC(O)R 9 ; N(R 9 )C(O)R 9a ; N(R 9 )S(O) 2 R 9a ; N(R 9 )S(O)R 9a ; N(R 9 )C(O)N(R 9a R 9b ); N(R 9 )C(O)OR 9a ; OC(O)N(R 9 R 9a ); or Ci_6 alkyl substituted with one
  • R 9 , R 9a , R 9b are independently selected from the group consisting of R 9c ; and R 9d , provided that at least one of R 9 , R 9a , R 9b is R 9c ;
  • R 9c is T 2 ; or Ci_6 alkyl, wherein Ci_6 alkyl is substituted with one or more T 2 and optionally substituted with one or more R 8 ; R 7 , R 7a , R 7b , R 9d are independently selected from the group consisting of H; and Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more R 8 ;
  • R 8 is halogen; CN; C(O)OR 10 ; OR 10 ; C(O)R 10 ; C(O)N(R 10 R 10a ); S(O) 2 N(R 10 R 1 Oa ); S(O)N(R 10 R 10a ); S(O) 2 R 10 ; S(O)R 10 ; N(R 10 ) S (O) 2 N(R 10 V ob ); N(R 1 °) S (O)N(R 10 V ob ); SR 10 ; N(R 10 R 10a ); OC(O)R 10 ; N(R 10 )C(O)R 10a ; N(R 10 )S(O) 2 R 10a ; N(R 10 )S(O)R 10a ; N(R 10 )C(O)N(R 10a R 10b ); N(R 10 )C(O)OR 10a ; OC(O)N(R 10 R 10a ); or Ci_ 6 alky
  • R 10 , R 1Oa , R 10b are independently selected from the group consisting of H; and Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • T 2 is C3_7 cycloalkyl; 4 to 7 membered heterocyclyl; 8 to 11 membered heterobicyclyl; phenyl; naphthyl; indenyl; or indanyl, wherein T 2 is optionally substituted with one or more R 11 ;
  • Ci -6 alkyl N(R 12 )C(O)OR 12a ; OC(O)N(R 12 R 12a ); or Ci -6 alkyl, wherein Ci -6 alkyl is optionally substituted with one or more halogen which are the same or different;
  • R 12 , R 12a , R 12b are independently selected from the group consisting of H; and Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different.
  • Preferred and even more preferred compounds are those mentioned above.
  • PBK or "PB kinase” includes all members of the PBK family comprising class IA (e.g. PBK alpha, beta and delta), class IB (e.g. PBK gamma), class II (e.g. PI3KC2 alpha, beta and gamma) and class III (e.g. Vps34 yeast homologue).
  • PBK ⁇ means PBK ⁇ protein, the only member of PBK class IB (also referred to as pi 10- gamma).
  • a human cDNA encoding the PBK ⁇ protein of a 1050 amino acid residue long polypeptide was described (Stoyanow et al, 1995, Science 269:690-693).
  • the human PBK ⁇ protein is encoded by the PBKCG gene which comprises 10 exons and is located on chromosome 7q22 (Rratz et al., 2002, Blood 99:372-374).
  • PBK ⁇ means PBK ⁇ protein, a member of PBK class class IA (also referred to as pi 10- delta).
  • PBK ⁇ protein a member of PBK class class IA (also referred to as pi 10- delta).
  • a human cDNA encoding the PBK ⁇ protein of 1044 amino acids was reported (Vanhaesebroeck et al., 1997, Proc. Natl. Acad Sci. 94:4330-4335).
  • the human PBK ⁇ protein is encoded by the PBKCD gene which was mapped to chromosome Ip3.2 (Seki et al., 1997, DNA Research 4:355-358).
  • Yet another object of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prophylaxis of immunological, inflammatory, autoimmune, or allergic disorders.
  • preferred disorders are autoimmune diseases; organ and bone marrow transplant rejection; graft-versus-host disease; acute or chronic inflammation; pancreatitis; contact dermatitis; psoriasis; rheumatoid arthritis; multiple sclerosis; type I diabetes; inflammatory bowel disease; Crohn's disease; ulcerative colitis; systemic lupus erythematosus; asthma; chronic obstructive pulmonary disease (COPD); acute respiratory distress syndrome (ARDS); bronchitis; conjunctivitis; dermatitis; allergic rhinitis; acute gouty inflammation; cystic fibrosis; familial Mediterranean fever; tissue damage after bacterial infection; Sweet's syndrome; or anaphylaxis.
  • autoimmune diseases include organ and bone marrow transplant rejection; graft-versus-host disease; acute or chronic inflammation; pancreatitis; contact dermatitis; psoriasis; rheumatoid arthritis; multiple sclerosis; type I diabetes
  • RA rheumatoid arthritis
  • IBD inflammatory bowel disease
  • SLE systemic lupus erythematosus
  • psoriasis psoriasis
  • MS multiple sclerosis
  • COPD chronic obstructive pulmonary disease
  • RA Rheumatoid arthritis
  • RA is a chronic progressive, debilitating inflammatory disease that affects approximately 1% of the world's population.
  • RA is a symmetric polyarticular arthritis that primarily affects the small joints of the hands and feet.
  • pannus In addition to inflammation in the synovium, the joint lining, the aggressive front of tissue called pannus invades and destroys local articular strucrures (Firestein 2003, Nature 423:356-361).
  • IBD Inflammatory bowel disease
  • IBD is characterized by a chronic relapsing intestinal inflammation. IBD is subdivided into Crohn's disease and ulcerative colitis phenotypes.
  • Crohn disease involves most frequently the terminal ileum and colon, is transmural and discontinuous. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers. In approximately 10% of cases confined to the rectum and colon, definitive classification of Crohn disease or ulcerative colitis cannot be made and are designated 'indeterminate colitis.' Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Neutrophil-induced injuries may be prevented by the use of neutrophils migration inhibitors (Asakura et al, 2007, World J Gastroenterol. 13(15):2145-9).
  • SLE Systemic lupus erythematosus
  • T cell- mediated B-cell activation results in glomerulonephritis and renal failure.
  • Human SLE is characterized at early stages by the expansion of long-lasting autoreactive CD4 + memory cells (D'Cruz et al., 2007, Lancet 369(9561):587-596).
  • Psoriasis is a chronic inflammatory dermatosis that affects approximately 2% of the population. It is characterized by red, scaly skin patches that are usually found on the scalp, elbows, and knees, and may be associated with severe arthritis. The lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis (Sch ⁇ n et al., 2005, New Engl. J. Med. 352:1899-1912).
  • MS Multiple sclerosis
  • Asthma is a complex syndrome with many clinical phenotypes in both adults and children. Its major characteristics include a variable degree of air flow obstruction, bronchial hyperresponsiveness, and airway inflammation (Busse and Lemanske, 2001, N. Engl. J. Med. 344:350-362).
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • chronic inhalation of irritants causes an abnormal inflammatory response, remodeling of the airways, and restriction of airflow in the lungs.
  • the inhaled irritant is usually tobacco smoke, but occupational dust and environmental pollution are variably implicated (Shapiro 2005, N. Engl. J. Med. 352, 2016-2019).
  • Pancreatitis is the inflammation of the pancreas.
  • Acute pancreatitis is a condition that develops when the pancreas is damaged by inflammation that leads to swelling and sometimes to necrosis of part of the pancreas (Carroll et al., 2007. American Family Physiscian 75(1): 1513-1520).
  • acute pancreatitis widespread injury to the pancreas over many years may cause extensive scarring and destruction of the pancreas. It was demonstrated that PI3K ⁇ plays a role in a mouse model for pancreatitis.
  • mice lacking PI3K ⁇ The lethality of of the choline- deficient/ethionine-supplemented diet-induced pancreatitis was significantly reduced in mice lacking PI3K ⁇ (Lupia et al., 2004. Am. J. Pathol. 165(6):2003-2011).
  • Acute gouty inflammation is the consequence of the deposition of monosodium urate crystals in joints. Neutrophils appear to be the major effector of acute gout, accumulating in the joint fluid where they actively ingest urate crystals, aggregate and degranulate. Acute gouty inflammation as well as other diseases associated with crystal deposition like articular chondrocalcinosis, silicosis, soft tissue calcium deposit in patients with chronic renal failure, may be prevented by inhibition of neutrophils chemotaxis (Ryckman et al., 2003, Arthritis & Rheumatism 48 (8): 2310-20).
  • Cystic fibrosis is a hereditary disorder caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR), the product of which is a membrane protein thought to function as a chloride channel.
  • CFTR cystic fibrosis transmembrane conductance regulator
  • the lethal clinical manifestations are clearly related to the thick, infected mucous and chronic neutrophils-dominated airway inflammation.
  • An anti-inflammatory agent with direct effects on neutrophils may represent a good drug candidate for the clinical management of CF (Mclntosh et al., 1992, FASEB J 6:2775-82).
  • Familial Mediterranean Fever is an autosomal recessive disorder characterised by recurrent and reversible attacks of fever and serositis. The inflammatory episodes are characterized by massive influx of neutrophils into the serosal and synovial membranes. Secondary amyloidosis, a consequence of long-standing inflammation, is the most sever complication of the disease. Inhibitors of neutrophils activation may result beneficial for the amelioration of the disease (Molad et al, 2004, J. Investig. Med. 52(1):58-61).
  • Tissue damage after acute bacterial infection may partly result from excessive neutrophils infiltration and activation in the infected tissue.
  • bacteria in the kidney parenchyma trigger a burst of neutrophils extravascular migration.
  • renal scarring after acute bacterial pyelonephritis results from parenchymal damage by neutrophils.
  • Tissue damages following infections in pyelonephritis, osteomyelitis, endocaditis, endotoxic shock and acute respiratory distress syndrome may be prevented by inhibition of neutrophils activation (Bille et al., 1982, J. Infect. Dis. 146:220-6).
  • Sweet's syndrome (named acute febrile neutrophilic dermatosis) is characterized by a constellation of clinical symptoms which include pyrexia, elevated neutrophil count, tender erythematous skin lesions and a diffuse infiltrate consisting predominantly of mature neutrophils typically located in the upper dermis. Inhibition of neutrophils activation may represent a therapy for patient suffering from Sweet's syndrome (Cohen, 2007, Orphanet J. Rare Dis. 2:34).
  • Anaphylaxis is an acute systemic and severe type I hypersensitivity allergic reaction.
  • Anaphylactic shock is the most severe type of anaphylaxis.
  • Anaphylactic shock is a sudden, life-threatening allergic reaction associated with severe hypotension.
  • Platelet-activating factor (PAF) is implicated in the cardiovascular dysfunctions occurring in various shock syndromes, including anaphylaxis. Excessive production of the vasodilator NO causes inflammatory hypotension and shock.
  • eNOS the endothelial isoform of nitric oxide synthase, as a mediator of anaphylaxis and defines PBK as new potential targets for treating anaphylaxis (Cauwels et al., 2006, J. Clin. Invest. 116(8):2244-51).
  • PBK diseases and disorders associated especially with PBK are cancer, cardiovascular disorders metabolic diseases, neurodegenerative disorders or infectious diseases.
  • Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prophylaxis of cancer, metabolic diseases, neurodegenerative disorders, infectious diseases or cardiovascular disorders, more specifically myocardial infarction, stroke, ischemia or atherosclerosis.
  • Cancer comprises a group of diseases characterized by uncontrolled growth and spread of abnormal cells. All types of cancers generally involve some abnormality in the control of cell growth, division and survival, resulting in the malignant growth of cells. Key factors contributing to said malignant growth of cells are independence from growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis, and genome instability (Hanahan and Weinberg, 2000. The Hallmarks of Cancer. Cell 100, 57-70).
  • cancers are classified as hematological cancers (for example leukemias and lymphomas) and solid cancers such as sarcomas and carcinomas (for example cancers of the brain, breast, lung, colon, stomach, liver, pancreas, prostate, ovary).
  • hematological cancers for example leukemias and lymphomas
  • solid cancers such as sarcomas and carcinomas (for example cancers of the brain, breast, lung, colon, stomach, liver, pancreas, prostate, ovary).
  • Obesity and diabetes mellitus type 2 represent a steadily increasing health risk worldwide.
  • Leptin secreted by adipose tissue and acting in part through its hypothalamic receptor, integrates the energy state of peripheral organs and the action of the central nervous system inhibiting food intake and stimulating energy expenditure.
  • the pancreas-derived peptide hormone insulin enters the central nervous system (CNS) through the blood-brain barrier by receptor-mediated transport to regulate food intake, sympathetic activity and peripheral insulin action through the inhibition of hepatic gluconeogenesis and reproductive endocrinology.
  • PBK phosphatidylinositol 3-kinase
  • PBK inhibitors may turn beneficial in the treatment of diseases where the processes mentioned above are involved.
  • PBK protein kinase
  • the PBK pathway could be a novel target for the development of future anti- influenza drugs (Ehrhardt et al, 2007, J. Virol. 81 (7): 3058-67; Hale et al, 2006, PNAS 103,
  • Another object of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions selected from the group consisting of diseases and disorders associated with PBK, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to present invention or a pharmaceutically acceptable salt thereof.
  • Yet another object is a method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions selected from the group consisting of immunological; inflammatory; and allergic disorders, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to the present invention or a pharmaceutically acceptable salt thereof.
  • the one or more conditions are selected from the group consisting of autoimmune diseases; organ and bone marrow transplant rejection; graft-versus-host disease; acute or chronic inflammation; pancreatitis; contact dermatitis; psoriasis; rheumatoid arthritis; multiple sclerosis; type I diabetes; inflammatory bowel disease; Crohn's disease; ulcerative colitis; systemic lupus erythematosus; asthma; chronic obstructive pulmonary disease (COPD); acute respiratory distress syndrome (ARDS); bronchitis; conjunctivitis; dermatitis; and allergic rhinitis; acute gouty inflammation; cystic fibrosis; familial Mediterranean fever; tissue damage after bacterial infection; Sweet's syndrome; or anaphylaxis.
  • autoimmune diseases include organ and bone marrow transplant rejection; graft-versus-host disease; acute or chronic inflammation; pancreatitis; contact dermatitis; psoriasis; rheumatoi
  • RA rheumatoid arthritis
  • IBD inflammatory bowel disease
  • SLE systemic lupus erythematosus
  • psoriasis psoriasis
  • MS multiple sclerosis
  • COPD chronic obstructive pulmonary disease
  • Yet another object of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions selected from the group consisting of cancer; metabolic diseases; neurodegenerative disorders; infectious diseases and cardiovascular disorders, more specifically myocardial infarction, stroke, ischemia or atherosclerosis, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to the present invention or a pharmaceutically acceptable salt thereof.
  • treating or “treatment” is intended to refer to all processes, wherein there may be a slowing, interrupting, arresting, or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.
  • the compounds of the invention may also modulate in addition or alternatively immune cell activation via inhibition of PBK.
  • PBK ⁇ and PBK ⁇ are important roles of PBK ⁇ and PBK ⁇ in signaling and other functions of T cells, B cells, neutrophils, macrophages and mast cells indicate that these kinases are valid therapeutic targets for several inflammation-mediated diseases.
  • These diseases comprise rheumatoid arthritis (in which T cells, B cells and neutrophils are involved), systemic lupus erythematosus (in which neutrophils are involved), psoriasis (in which T cells, neutrophils and macrophages are engaged), multiple sclerosis (in which T cells, B cells and mast cells are implicated), asthma (for which T cell and mast cells are important), and chronic obstructive pulmonary disease (which involves neutrophils, macrophages and T cells) (Rommel et al, 2007, Nat. Rev. Immunology 7:191-201).
  • PBK ⁇ and PBK ⁇ as potential drug targets for specific diseases has been experimentally established by testing the respective PBK-null mice in animal disease models. Additional pharmacological confirmation was obtained by using small molecule PBK inhibitors in wild-type mice in which inflammatory diseases were experimentally induced. Camps and colleagues used structure-based drug design to develop a potent small molecule inhibitor of PIK3 ⁇ referred to as AS-605240 (Camps et al, 2005. Nat. Med. l l(9):936-43).
  • Pik3cg-null mice were protected against arthritis induced by collagen II- specif ⁇ c antibodies, a murine model of lymphocyte-independent rheumatoid arthritis (RA) associated with neutrophil activation. The effect was associated with impaired neutrophil chemotaxis.
  • Treatment of wildtype mice with oral AS-605420 resulted in reduced clinical and histologic signs of collagen II-antibody-induced arthritis, similar to that seen in the Pik3cg- null mice.
  • Oral AS-605240 also resulted in decreased joint inflammation and damage in a distinct mouse model of lymphocyte-dependent rheumatoid arthritis induced by direct collagen II injection.
  • PIK3CG inhibition operates on both the neutrophil and lymphocyte arms of chemokine signaling pathways, and thus may be of therapeutic value in various chronic inflammatory diseases.
  • PI3 kinases The involvement of PI3 kinases in allergic inflammatory diseases such as asthma was demonstrated through pharmacological inhibition by non-selective PI3K inhibitors such as wortmannin and LY294002. However, these compounds were not selective enough to discriminate between distinct PI3K isoforms (Walker et al., 2006, Drug Discovery Today: Disease Mechanisms, 3(l):63-69).
  • PI3K ⁇ plays a role in neutrophil inflammatory responses. Inhibition of PI3K ⁇ blocked both fMLP- and TNF l ⁇ - induced neutrophil superoxide generation and elastase exocytosis (Sadhu et al., 2003, Biochem. Biophys. Res. Commun. 2003 Sep 5;308(4):764-769).
  • PI3K ⁇ The essential role of PI3K ⁇ in allergic responses was demonstrated by genetic and pharmacological inactivation of PI3K ⁇ in mast cells. This inhibition leads to to defective SCF-mediated in vitro proliferation, adhesion and migration, and to impaired allergen-IgE- induced degranulation and cytokine release. Moreover, inactivation of PI3K ⁇ protects mice against anaphylactic allergic responses. Taken together, these studies suggest PI3K ⁇ as a target for therapeutic intervention in allergy and mast-cell-related diseases (AIi et al., 2004, Nature 431 :1007-1011).
  • diseases and disorders are preferred which are associated with PI3K delta and/or PI3K gamma.
  • inflammatory and immunoregulatory disorders rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, multiple sclerosis, asthma and chronic obstructive pulmonary disease.
  • PI3K also plays a role with regard to cancer and cardiovascular disorders.
  • PI3K ⁇ has been proposed as a possible target for pharmacological intervention in the primary and secondary prevention of human atherosclerotic cardiovascular disease.
  • Atherosclerosis and its sequelae, including myocardial infarction and stroke, are the leading causes of mortality and morbidity in the developed world.
  • PI3K ⁇ is activated in macrophages by oxidized LDL, agonists, chemokines and inflammatory mediators commonly implicated in atherogenesis.
  • Genetic ablation of PBKg in hypercholesterolemic mice (apoE-/-) results in reduced atherosclerotic lesions. In addition to retarding plaque progression, it is of clinical relevance the possibility that the inhibition of PBK might affect plaque stability (Chang et al., 2007, PNAS 104 (19):8077-82).
  • PBK ⁇ phosphatidylinositol(3,4,5)- trisphosphate
  • PIP3 phosphatidylinositol(3,4,5)- trisphosphate
  • the study of mice lacking PBK ⁇ revealed that the PIP3 signaling pathway controls immune cell and vascular functions such as respiratory burst, cell recruitment, mast cell reactivity, platelet aggregation, endothelial activation and smooth muscle cell contractility. The specificity of these events suggests that inhibition of PBK ⁇ may be beneficial for major cardiovascular disorders such as hypertension (Hirsch et al., 2006, Thromb. Haemost. 95(l):29-35).
  • MI Myocardial infarction
  • I/R biphasic ischemia/reperfusion
  • This compound potently inhibits edema and inflammation in response to multiple mediators known to play a role in myocardial infarction. Importantly, this was achieved when dosing after myocardial reperfusion (up to 3 hours after), the same time period when patients are most accessible for therapeutic intervention (Doukas et al., 2006, PNAS 103(52):19866-19871; Doukas et al., 2007, Biochem. Soc. Trans. 35(Pt2):204- 206; Palanki et al., 2007, J. Med. Chem. 50(18)4279-4294).
  • PIK3CA mutants promote cell growth and invasion of human cancer cells and that treatment with the non-selective PBK inhibitor LY294002 abrogated PIK3A signaling and preferentially inhibited growth of PBKCA mutant cells (Samuels et al., 2005, Cancer Cell
  • the present invention provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.
  • R 1 , R 2 , R 3 are independently selected from the group consisting of H; halogen; CN; C(O)OR 4 ;
  • Ci_6 alkyl wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • R 4 , R 4a , R 4b are independently selected from the group consisting of H; and Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different; T 1 is 4 to 7 membered heterocyclyl; 8 to 11 membered heterobicyclyl; phenyl; naphthyl; indenyl; or indanyl; wherein T 1 is optionally substituted with one or more R 5 and/or one or more R 6 ;
  • Ci_6 alkyl wherein Ci_6 alkyl is optionally substituted with one or more R 8 ;
  • R 6 is T 2 ; C(O)OR 9 ; OR 9 ; C(O)R 9 ; C(O)N(R 9 R 9a ); S(O) 2 N(R 9 R 9a ); S(O)N(R 9 R 9a ); S(O) 2 R 9 ;
  • N(R 9 )C(O)R 9a N(R 9 )S(O) 2 R 9a ; N(R 9 )S(O)R 9a ; N(R 9 )C(O)N(R 9a R 9b ); N(R 9 )C(O)OR 9a ;
  • R 9 , R 9a , R 9b are independently selected from the group consisting of R 9c ; and R 9d , provided that at least one of R 9 , R 9a , R 9b is R 9c ;
  • R 9c is T 2 ; or Ci_6 alkyl, wherein Ci_6 alkyl is substituted with one or more T 2 and optionally substituted with one or more R 8 ;
  • R 7 , R 7a , R 7b , R 9d are independently selected from the group consisting of H; and Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more R 8 ;
  • R 8 is halogen; CN; C(O)OR 10 ; OR 10 ; C(O)R 10 ; C(O)N(R 10 R 10a ); S(O) 2 N(R 10 R 1 Oa );
  • Ci -6 alkyl wherein Ci -6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • R 10 , R 1Oa , R 10b are independently selected from the group consisting of H; and Ci_ 6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • T 2 is C3-7 cycloalkyl; 4 to 7 membered heterocyclyl; 8 to 11 membered heterobicyclyl; phenyl; naphthyl; indenyl; or indanyl, wherein T 2 is optionally substituted with one or more R 11 ;
  • R 12 , R 12a , R 12b are independently selected from the group consisting of H; and Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different.
  • Preferred and even more preferred compounds are those mentioned above.
  • “Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered orally.
  • Saline and aqueous dextrose are preferred carriers when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid carriers for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained- release formulations and the like.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.
  • a pharmaceutical composition of the present invention may comprise one or more additional compounds as active ingredients like one or more compounds of formula (I) not being the first compound in the composition or PBK inhibitors.
  • active ingredients for use in combination with other therapies for the treatment of immune, inflammatory, allergic disorders may include steroids, leukotriene antagonists, anti-histamines, cyclosporine or rapamycin.
  • the compounds of formula (I) can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • any of the usual pharmaceutical media may be employed, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
  • oral liquid preparations such as, for example, suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
  • tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.
  • the active compounds can also be administered intranasally, for example, as liquid drops or spray.
  • the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • Compounds of formula (I) may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention.
  • oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
  • compounds of formula (I) are administered orally.
  • the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
  • the compounds of the formula (I) can be purified by customary purification procedures, for example by distillation, recrystallization or chromatography.
  • the starting compounds for the preparation of the compounds of the formula (I) are commercially available or can be prepared according to or analogously to literature procedures.
  • a general route for the synthesis of compounds of formula (I) may start with triazoles of formula (III), which are readily available by conventional methods for the preparation of this type of heterocycle. Such methods are well known for the person skilled in the art.
  • T 1 -B(OH) 2 and T 1 -B(OR) 2 as suitable starting materials for the synthesis of preferred compounds of the present invention may be purchased from commercially available sources such as CombiBlocks, Sigma Aldrich, AlfaAesar or be synthesized by one skilled in the art and either isolated or used in situ.
  • the preparation of triazoles of formula (III) may start with a pyridine of formula (IV) which is reacted with ethoxycarbonyl isothiocyanate to yield compounds of formula (II) and after cyclisation in the presence of hydroxylamine the triazoles of formula (II) as outlined in Scheme 2.
  • Another aspect of the present invention is a method for the preparation of a compound according to formula (I), comprising the steps of
  • the preferred compounds of the present invention may be synthesised by coupling of the triazole [3] with the respective aryl boronic acids/esters or bromides under Suzuki reaction conditions using Pd(PPhS) 2 Cl 2 as catalyst and sodium carbonate as base in DME/H 2 O/EtOH at 100-150 0 C to afford the desired products [4], Scheme 4.
  • aryl boronic acids/esters or bromides were either selected from those commercially available or synthesised by elaboration of commercially available intermediates using the methods shown below.
  • NMR spectra were obtained on a Brucker dpx400.
  • LCMS was carried out on an Agilent 1100 using a ZORBAX ® SB-C18, 4.6 x 150 mm, 5microns, ZORBAX ® SB-C18, 4.6 x 75 mm, 3.5 micron or GeminiTM C 18, 3 x 30 mm, 3 microns column.
  • Column flow was 1.0 or 1.2 mL/min. and solvents used were water and acetonitrile (0.1% formic acid) with an injection volume of 3 or lOul. Wavelengths were 254 and 210nm.
  • the crude reaction was either partitioned between water and ethyl acetate, the phases separated and the organic layer washed with brine, dried over magnesium sulfate, filtered and the solvent removed in vacuo or precipitated by addition of water, the precipitate collected by filtration and washed with ethyl acetate and methanol.
  • the crude residues were either purified by flash chromatography or preparative HPLC if required to afford the desired products.
  • the crude reaction was then either partitioned between water and ethyl acetate, the phases separated and the organic layer washed with brine, dried over magnesium sulfate, filtered and the solvent removed in vacuo or precipitated by addition of water, the precipitate collected by filtration and washed with ethyl acetate and methanol.
  • the crude residues were either purified by flash chromatography or preparative HPLC if required to afford the desired products.
  • test compounds as described in example 1 can be tested in the PBK kinobeads assay as described (EP-A 1 887 359). Briefly, test compounds (at various concentrations) and the affinity matrix with the immobilized phenylthiazole ligand 1 are added to cell lysate aliquots and allowed to bind to the proteins in the lysate sample. After the incubation time the beads with captured proteins are separated from the lysate. Bound proteins are then eluted and the presence of PBK enzymes are detected and quantified using a specific antibody in a dot blot procedure and the Odyssey infrared detection system.
  • PBK lipid kinase activity can be measured using purified or recombinant enzyme in a solution-based assay with phopholipid vesicles.
  • reaction is terminated by the addition of acidified organic solvents and subsequent phase separation by extraction or thin layer chromatography analysis (Carpenter et al., 1990, J. Biol. Chem. 265, 19704-19711).
  • Another assay described in the art is based on the phosphate transfer from radiolabeled ATP to phosphatidylinositol immobilized on plates.
  • This assay type also uses recombinant PBK gamma enzyme but can be performed in a high throughput mode (Fuchikami et al., 2002, J. Biomol. Screening 7, 441-450).

Abstract

La présente invention concerne des composés de formule (I) dans laquelle T1 et R1 à R3 sont tels que définis dans la description et les revendications. Lesdits composés sont utiles en tant qu’inhibiteurs de la protéine kinase, en particulier de PI3K, pour le traitement ou la prophylaxie de troubles immunologiques, inflammatoires, auto-immuns, ou allergiques. L’invention concerne également des compositions pharmaceutiques comportant lesdits composés, la préparation de tels composés ainsi que leur production et utilisation en tant que médicaments.
PCT/EP2009/059076 2008-07-15 2009-07-15 Amino triazoles substitués en position 7 en tant qu’inhibiteurs de pi3k WO2010007100A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08160411 2008-07-15
EP08160411.8 2008-07-15
US17033409P 2009-04-17 2009-04-17
US61/170,334 2009-04-17

Publications (1)

Publication Number Publication Date
WO2010007100A1 true WO2010007100A1 (fr) 2010-01-21

Family

ID=40111147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/059076 WO2010007100A1 (fr) 2008-07-15 2009-07-15 Amino triazoles substitués en position 7 en tant qu’inhibiteurs de pi3k

Country Status (1)

Country Link
WO (1) WO2010007100A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838055B2 (en) 2002-07-03 2010-11-23 Danisco Sweeteners Oy Crystallization of polyol compositions, crystalline polyol composition product and use thereof
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
US8501936B2 (en) 2009-06-05 2013-08-06 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
WO2014198594A1 (fr) * 2013-06-10 2014-12-18 Bayer Pharma Aktiengesellschaft Nouveaux composés destinés au traitement du cancer
US9751854B2 (en) 2014-01-14 2017-09-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2018148626A1 (fr) * 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2020215094A1 (fr) 2019-04-18 2020-10-22 The Johns Hopkins University Dérivés de 2-amino-pyrazolyl-[1,2,4]triazolo[1,5 a] pyridine substitués et leur utilisation
CN113508109A (zh) * 2019-03-22 2021-10-15 劲方医药科技(上海)有限公司 取代的杂环酰胺类化合物，其制法与医药上的用途
WO2022081522A1 (fr) * 2020-10-13 2022-04-21 The Johns Hopkins University Dérivés de 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophène-2-carboxamide substitués et leur utilisation
US11767322B2 (en) 2020-10-19 2023-09-26 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2006038116A2 (fr) * 2004-10-07 2006-04-13 Warner-Lambert Company Llc Agents antibacteriens
WO2007095588A1 (fr) * 2006-02-14 2007-08-23 Novartis Ag Inhibiteurs de kinase pi-3 et leurs procédés d'utilisation
WO2008025821A1 (fr) * 2006-08-30 2008-03-06 Cellzome Limited Dérivés de triazole en tant qu'inhibiteurs de kinase
WO2009068482A1 (fr) * 2007-11-27 2009-06-04 Cellzome Limited Aminotriazoles comme inhibiteurs de p13k

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2006038116A2 (fr) * 2004-10-07 2006-04-13 Warner-Lambert Company Llc Agents antibacteriens
WO2007095588A1 (fr) * 2006-02-14 2007-08-23 Novartis Ag Inhibiteurs de kinase pi-3 et leurs procédés d'utilisation
WO2008025821A1 (fr) * 2006-08-30 2008-03-06 Cellzome Limited Dérivés de triazole en tant qu'inhibiteurs de kinase
WO2009068482A1 (fr) * 2007-11-27 2009-06-04 Cellzome Limited Aminotriazoles comme inhibiteurs de p13k

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. A. BARTH ET. AL.: "Synthese von Aminopyrazolo- und Aminotriazolo[2,3-a]pyridinen.", JOURNAL FÜR PRAKTISCHE CHEMIE, vol. 317, 1975, pages 561 - 566, XP002508429 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838055B2 (en) 2002-07-03 2010-11-23 Danisco Sweeteners Oy Crystallization of polyol compositions, crystalline polyol composition product and use thereof
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
US8501936B2 (en) 2009-06-05 2013-08-06 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
US8633173B2 (en) 2009-06-05 2014-01-21 Cephalon, Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
WO2014198594A1 (fr) * 2013-06-10 2014-12-18 Bayer Pharma Aktiengesellschaft Nouveaux composés destinés au traitement du cancer
CN105246891A (zh) * 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
JP2016521737A (ja) * 2013-06-10 2016-07-25 バイエル・ファルマ・アクティエンゲゼルシャフト 癌を治療するための新規な化合物
US9751854B2 (en) 2014-01-14 2017-09-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9802960B2 (en) 2014-01-14 2017-10-31 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10538533B2 (en) 2014-01-14 2020-01-21 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN110520423A (zh) * 2017-02-13 2019-11-29 百时美施贵宝公司 作为激酶抑制剂的氨基三唑并吡啶
JP7097373B2 (ja) 2017-02-13 2022-07-07 ブリストル－マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのアミノトリアゾロピリジン
WO2018148626A1 (fr) * 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
JP2020507582A (ja) * 2017-02-13 2020-03-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼ阻害剤としてのアミノトリアゾロピリジン
KR102549952B1 (ko) 2017-02-13 2023-06-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노트리아졸로피리딘
US10913738B2 (en) 2017-02-13 2021-02-09 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
AU2018217488B2 (en) * 2017-02-13 2021-09-23 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
KR20190117006A (ko) * 2017-02-13 2019-10-15 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노트리아졸로피리딘
EA039808B1 (ru) * 2017-02-13 2022-03-16 Бристол-Маерс Сквибб Компани Аминотриазолопиридины в качестве ингибиторов киназ
CN110520423B (zh) * 2017-02-13 2022-08-23 百时美施贵宝公司 作为激酶抑制剂的氨基三唑并吡啶
CN113508109A (zh) * 2019-03-22 2021-10-15 劲方医药科技(上海)有限公司 取代的杂环酰胺类化合物，其制法与医药上的用途
CN113508109B (zh) * 2019-03-22 2023-02-10 劲方医药科技(上海)有限公司 取代的杂环酰胺类化合物，其制法与医药上的用途
WO2020215094A1 (fr) 2019-04-18 2020-10-22 The Johns Hopkins University Dérivés de 2-amino-pyrazolyl-[1,2,4]triazolo[1,5 a] pyridine substitués et leur utilisation
WO2022081522A1 (fr) * 2020-10-13 2022-04-21 The Johns Hopkins University Dérivés de 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophène-2-carboxamide substitués et leur utilisation
US11767322B2 (en) 2020-10-19 2023-09-26 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors

Similar Documents

Publication Publication Date Title
WO2010007099A1 (fr) Dérivés de 2-aminoimidazo[1,2-b]pyridazine en tant qu’inhibiteurs de pi3k
EP2222674B1 (fr) Amino triazoles en tant qu'inhibiteurs pi3k
WO2010007100A1 (fr) Amino triazoles substitués en position 7 en tant qu’inhibiteurs de pi3k
EP2057158B1 (fr) Dérivés de triazole en tant qu'inhibiteurs de kinase
JP5511805B2 (ja) ｐ３８キナーゼ阻害剤としてのピロロ［２，３−ｃ］ピリジン誘導体
WO2010092015A1 (fr) Dérivés d'urée-triazolo[1,5-a]pyridine en tant qu'inhibiteurs de pi3k
WO2010057877A1 (fr) Triazolo[1,5-a]pyridines 7-pyridinyle- ou phényl-substituées comme inhibiteurs de pi3k
WO2008025820A1 (fr) Dérivés d'aminopyridine en tant qu'inhibiteurs de kinase
EP2760863A1 (fr) Dérivés de pyrazolo[4,3-c]pyridine comme inhibiteurs de kinases
AU2002211827B2 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
JP5113751B2 (ja) ｐ３８キナーゼ阻害剤として有用な二環性複素環化合物
US8022085B2 (en) Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
WO2010133534A1 (fr) Composés substitués amino bicycliques utiles comme inhibiteurs de pi3k
CA3195292A1 (fr) Modulateurs de la voie de reponse de stress integree
CA3195293A1 (fr) Modulateurs de la voie de reponse integree au stress
EP0470078A1 (fr) 1,4-dihydropyridines
JPH04503515A (ja) １，４―ジヒドロピリジン類

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09780642

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09780642

Country of ref document: EP

Kind code of ref document: A1